


PARTUM

Postpartum Aspirin to Reduce
Thromboembolism Undue Morbidity Trial

TRIAL DESIGN



Is your patient a possible candidate?

INCLUSION CRITERIA

ONE (or more) First Order Criterion:

1. Mild inherited thrombophilia prior to enrolment:
 - a. Heterozygous factor V Leiden or
 - b. Heterozygous prothrombin gene variant or
 - c. Protein C deficiency or
 - d. Protein S deficiency
2. Bedrest (90% of the time) for ≥ 7 days any time during pregnancy

OR

TWO (or more) Second Order Criteria:

1. Pre-pregnancy BMI ≥ 30 kg/m²
2. Smoking ≥ 5 cigarettes/day (includes the 3 months before pregnancy)
3. Past superficial vein thrombosis (not DVT or varicose veins)
4. Pre-eclampsia (BP $\geq 140/90$ mmHg and proteinuria)
5. Stillbirth in current pregnancy (loss > 20 weeks)
6. SGA infant < 3 rd percentile
7. Unplanned cesarean delivery
8. Postpartum infection
9. Postpartum hemorrhage > 1000 mL

PARTUM

Postpartum Aspirin to Reduce
Thromboembolism Undue Morbidity Trial

Is your patient a possible candidate?

EXCLUSION CRITERIA

1. < 18 years of age
2. Need for postpartum LMWH prophylaxis:
 - a. Past VTE
 - b. Mechanical heart valve(s)
 - c. Antiphospholipid syndrome
 - d. High-risk inherited thrombophilia
 - i. Antithrombin deficiency
 - ii. Homozygous factor V Leiden
 - iii. Homozygous prothrombin gene mutation
 - iv. Compound heterozygosity factor V Leiden and prothrombin gene mutation
 - v. Any combination of 2 or more thrombophilias
3. Need for postpartum ASA:
 - a. Past myocardial infarction
 - b. Past ischemic stroke or transient ischemic attack (TIA)
4. Contraindication to ASA:
 - a. Known ASA allergy
 - b. Past gastrointestinal ulcer
 - c. Platelet count < 50 x 10⁹/L at any time during the current pregnancy or postpartum
 - d. Active bleeding at any site, excluding normal vaginal bleeding, at the time of randomization postpartum
 - e. Most recent known hemoglobin ≤ 70 g/L during the current pregnancy or postpartum
 - f. Severe hypertension (SBP > 200mm/hg and/or DBP > 120mm/hg)
5. More than 48 hours since delivery
6. Received more than 2 doses of LMWH since delivery

Note: Pneumatic compression devices, graduated compression stockings and NSAIDS are allowed

Please spread the word!

If you are interested, please contact the research team:

OMNI Research Coordinators

Rosemary: (613) 737-8899 x75866; Sara: (613) 737-8899 x77060

OMNI pager: 1-855-266-7243 then code 666474#

OMNI email: omniresearch@toh.ca

Study duration:

May 9 - Nov 18, 2022

The Ottawa
Hospital



OMNI
Obstetrics & Maternal
Newborn Investigations
Affiliated with uOttawa